Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01665794
Recruitment Status : Recruiting
First Posted : August 15, 2012
Last Update Posted : April 29, 2019
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Multiple Myeloma Research Foundation
Information provided by (Responsible Party):
University of Chicago

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 1, 2020
Estimated Study Completion Date : November 1, 2022